Header cover image

Chinese (SSE) Drug Retail Industry Analysis

UpdatedApr 13, 2024
DataAggregated Company Financials
  • 7D0.9%
  • 3M-7.2%
  • 1Y-19.9%
  • YTDn/a

In the last week, the Drug Retail industry is up 1.6%, with Yifeng Pharmacy Chain up 6.4%. In the past year, the industry is down 21%. Earnings are forecast to grow by 20% annually.

Industry Valuation and Performance

Has the Chinese Drug Retail Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 13 Apr 2024CN¥117.1bCN¥114.8bCN¥5.2b21.8x22.5x1x
Mon, 11 Mar 2024CN¥113.5bCN¥115.9bCN¥5.8b19.2x19.5x1x
Wed, 07 Feb 2024CN¥116.7bCN¥116.0bCN¥5.7b20.5x20.4x1x
Fri, 05 Jan 2024CN¥132.0bCN¥116.0bCN¥5.7b22.7x23x1.1x
Sun, 03 Dec 2023CN¥131.0bCN¥116.0bCN¥5.7b23x22.9x1.1x
Tue, 31 Oct 2023CN¥117.1bCN¥113.6bCN¥5.7b22.1x20.6x1x
Thu, 28 Sep 2023CN¥121.0bCN¥113.6bCN¥5.7b23x21.3x1.1x
Sat, 26 Aug 2023CN¥124.8bCN¥110.4bCN¥5.5b26.2x22.7x1.1x
Mon, 24 Jul 2023CN¥127.4bCN¥109.7bCN¥5.4b26.7x23.4x1.2x
Wed, 21 Jun 2023CN¥133.3bCN¥109.7bCN¥5.4b28.1x24.5x1.2x
Fri, 19 May 2023CN¥129.5bCN¥109.7bCN¥5.4b26.8x23.8x1.2x
Sun, 16 Apr 2023CN¥146.2bCN¥95.3bCN¥4.4b39.6x33.1x1.5x
Tue, 14 Mar 2023CN¥143.2bCN¥90.3bCN¥4.0b34.9x35.6x1.6x
Thu, 09 Feb 2023CN¥136.8bCN¥90.3bCN¥4.0b33.8x34x1.5x
Sat, 07 Jan 2023CN¥152.6bCN¥90.3bCN¥4.0b39.4x37.9x1.7x
Mon, 05 Dec 2022CN¥163.5bCN¥90.3bCN¥4.0b40.6x40.6x1.8x
Wed, 02 Nov 2022CN¥130.8bCN¥90.3bCN¥4.0b33.1x32.5x1.4x
Fri, 30 Sep 2022CN¥112.7bCN¥85.6bCN¥3.8b34.8x29.5x1.3x
Sun, 28 Aug 2022CN¥117.7bCN¥81.5bCN¥3.7b38.1x31.8x1.4x
Tue, 26 Jul 2022CN¥115.8bCN¥80.8bCN¥3.7b36.9x31x1.4x
Thu, 23 Jun 2022CN¥117.9bCN¥80.8bCN¥3.7b37.5x31.6x1.5x
Sat, 21 May 2022CN¥98.4bCN¥80.8bCN¥3.7b30.1x26.4x1.2x
Mon, 18 Apr 2022CN¥93.2bCN¥75.3bCN¥4.1b25.9x23x1.2x
Wed, 16 Mar 2022CN¥104.7bCN¥74.7bCN¥4.1b29.4x25.7x1.4x
Fri, 11 Feb 2022CN¥124.2bCN¥74.7bCN¥4.1b35.4x30.4x1.7x
Sun, 09 Jan 2022CN¥138.9bCN¥74.7bCN¥4.1b39.2x34x1.9x
Tue, 07 Dec 2021CN¥119.1bCN¥74.7bCN¥4.1b31.4x29.2x1.6x
Thu, 04 Nov 2021CN¥129.1bCN¥74.7bCN¥4.1b33.9x31.6x1.7x
Sat, 02 Oct 2021CN¥126.5bCN¥72.0bCN¥4.2b30.5x30.3x1.8x
Mon, 30 Aug 2021CN¥128.5bCN¥72.0bCN¥4.2b30.9x30.8x1.8x
Tue, 06 Jul 2021CN¥135.3bCN¥67.1bCN¥3.9b32.9x34.4x2x
Price to Earnings Ratio


Total Market Cap: CN¥159.0bTotal Earnings: CN¥3.8bTotal Revenue: CN¥65.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Chinese Drug Retail Industry Price to Earnings3Y Average 29.2x202220232024
Current Industry PE
  • Investors are pessimistic on the Chinese Drug Retail industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 22.6x which is lower than its 3-year average PE of 29.2x.
  • The 3-year average PS ratio of 1.5x is higher than the industry's current PS ratio of 1.0x.
Past Earnings Growth
  • The earnings for companies in the Drug Retail industry have grown 11% per year over the last three years.
  • Revenues for these companies have grown 21% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does Chinese Drug Retail compare with similar industries?

CN Market-2.72%
Consumer Staples-5.27%
Food and Staples Retail-1.48%
Drug Retail0.92%
Food Retail-2.61%
Food Distributors-6.43%
Big Box Super Stores-7.31%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
603939 Yifeng Pharmacy ChainCN¥42.836.4%
2727 Yixintang Pharmaceutical GroupCN¥20.134.1%
605266 Jianzhijia Pharmaceutical Chain GroupCN¥45.811.3%
600833 Shanghai No.1 PharmacyLtdCN¥11.081.3%
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.